All News

#ACR25 Clinical Review by Prof Coates @DrLauraCoates to be applied tomorrow! Early Diagnosis/Tx Abstr#2689 EHR study = IL-17i could prevent #PsA vs IL-23/TNFi Abstr#576 Oligo → Polyarthritis progression in women, no DMARD, enthesitis, dactylitis, nail psoriasis @RheumNow https://t.co/e1hCERpCNW

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Nice to see a Dietary intervention study in the "Top Abstracts That Will Change My Practice in the Near Future" by L. Coates for Year in Preview Small RCT but fibres significantly improve response to treatment in the MTX treated RA group with a mean reduction of DAS28 of https://t.co/vMeIAK1P5u

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Clinical Year in Preview SpA: no difference in efficacy rotating vs switching bDMARD MoA for next steps @RheumNow #ACR25 #LB09 https://t.co/shCLgk7Yqz

Links:

Jiha Lee JihaRheum ( View Tweet)
Do biologics prevent PsA? Retro cohort analysis EHR through natural language processing 5 years trends PsO treated w/ IL-17i had lower incidence of PsA/IA than pts treated w/ IL-23i, IL-12/23i, or TNFi therapies Adjustment on several confounding Prospective data heavily https://t.co/W9MFaWNbWC

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
ACR25 coming to a close with Clinical Year in Preview For PsA, can biologics prevent damage? If so, which one? Difficult to answer often b/c confounding by indication. NLP-informed propensity matching beyond demographics for clinical factors like BSA @RheumNow #ACR25 A#2689 https://t.co/jjpb0kTo34

Links:

Jiha Lee JihaRheum ( View Tweet)
#YearInPreview at #ACR25 @DrLauraCoates introduces the session with a teaser for work that will be presented later today. Are we entering an era in which we will be able to prevent #PsA? Find out more at 12:00 today, Abs #2689 @RheumNow https://t.co/GDTBGNTCCd

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

Rheum Now Rheumatology Round-Up — LIVE Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheumatology’s most trusted voices: this Friday, Oct 31 at 12 PM CST for break down of the latest breakthroughs and hottest topics in rheumatology from #ACR25. 📡 Live https://t.co/GXxmtoluBc
Dr. John Cush RheumNow ( View Tweet)
The DIPSA study: can diet improve PsA? Finally a RCT, and the general message is Loose weight, regardless of the diet! 3 arms: -Mediterranean diet 31pts -Low-calorie Dietary Approaches (DASH-LC) 30pts -Standard of care 31pts Primary outcome change in DAPSA wk 12 DASH-LC https://t.co/XH9Xdn0g96

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
In a U.S. axSpA cohort (n=4,799), women had a 24% higher adjusted risk of TNFi discontinuation vs men especially under age 65. No sex differences seen for IL-17i or JAKi, though sample sizes were small. Highlights need for sex-informed treatment strategies. Abstract#2634 https://t.co/58Dw3nFCsf

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Fukui et al. CorEvitas study. 12076 RA patients. Propensity score matching. Kidney dysfunction (eGFR<60) reduced chance of CDAI remission (HR 0.71) or remission/LDA (HR 0.88) @RheumNow #ACR25 Abstr#2640 https://t.co/uvTjOQlGD7

Links:

Richard Conway RichardPAConway ( View Tweet)
Dr. LRoss presents the SCTC SSc Heart Involvement classification criteria ♥️Criteria score >/= 11pts 🔸SN 77.8%; SP 95.9% 🔸OR 82.6 Huge endeavor towards standardization of SHI to help improve patient outcomes in the future 👏👏 #ACR25 @RheumNow https://t.co/QrgYlksjZB

Links:

sheila RHEUMarampa ( View Tweet)
Sjögren’s: two Phase 3 RCTs (NEPTUNUS-1 [QM], -2 [Q3M]) test Ianalumab (BAFF/BAFF-R) vs placebo. ΔESSDAI at 48wk: Ianalumab QM > PBO, statistically significant But ΔESSDAI ≈ 0.5–1 pt (vs PBO) below MCII (≥ 3) Promising biology, modest clinical gain #ACR25 @RheumNow LB24 https://t.co/8y580ch9iJ

Links:

Jiha Lee JihaRheum ( View Tweet)
Sjogren’s disease: is it maybe true you need to still have some salivary function left to get benefit from therapy? Ianalumab (BAFF inh) ph3 NEPTUNUS-1/2 Very decent on primary (ESSDAI) & we will see this Salivary flow only improved when some at baseline #ACR25 LB24 @RheumNow https://t.co/uGwKdN3Dsh

Links:

David Liew drdavidliew ( View Tweet)
#ACR25 Abstr#LB24 The first Phase 3 RCTs in #Sjogren meeting primary endpoint! In moderate-to-severe activity, both RCTs = improvement in ESSDAI vs PBO (pooled effect -1.2 reduction). High PBO rate. PGA, PaGA & Stimulated Salivary Flow) improved. No diff in ESSPRI/FACIT @RheumNow https://t.co/rAs6NeXDIn

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Use of AI in AxSpA imaging for diagnosis. ASembleNet, a hybrid deep learning model, achieved 99% accuracy on coronal and 98.1% on axial MRI for AS classification, outcomes higher than ResNet50, Xception, and InceptionV3. Validated on ASAS cases, with Grad-CAM interpretability and https://t.co/yU8shaIdP2

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Grader-Beck et al. Ianalumab in Sjogren's disease. NEPTUNUS 1 and 2 studies. 779 patients. Met primary endpoint ESSDAI. Big placebo effect also. Patient and physician global also improved. @RheumNow #ACR25 Abstr#LB24 https://t.co/klhxXW4Jfh

Links:

Richard Conway RichardPAConway ( View Tweet)
Fighting fire with butyrate 🔥🚒 ♦️probiotics and prebiotics Dr. Nisha Manek on inflammation and butyrate - it reduces gut inflamm thru the NFKB pathway #ACR25 @RheumNow https://t.co/19XTrKn1iN

Links:

sheila RHEUMarampa ( View Tweet)
Autologous CAR-Treg in RA, without any lymphodepletion preRx Early data from ph1, single dose Good initial response, stopped RA Rx, but some rebound Clearly work ongoing but excitement re: - CAR-Treg - RA as target dx - no lymphodepletion @minnakohlermd #ACR25 LB23 @RheumNow https://t.co/azmlFNU02R

Links:

David Liew drdavidliew ( View Tweet)
REGULATE RA SBT-77-701 Engineered Treg cell in Refractory RA population 6patients Safety and tolerability: No DLT, CRS or ICANS Efficacy Reduction >50% in TJC and SJC 67% reduction of DAS-CRP >=2 stained up to wk 24 Impressive in pts for whom it works, yet a couple seem to https://t.co/lQAQABPhg0

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×